%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-08-09T11:08:39-04:00
2017-08-09T11:08:41-04:00
2017-08-09T11:08:41-04:00
Adobe InDesign CC 2017 (Windows)
uuid:3cd08a7e-72a7-4f09-85e3-fc4f6758ae6a
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:312172e8-7017-4042-aa60-c8087c0c6b89
proof:pdf
xmp.iid:ae06694f-630c-bf47-a76f-51f21e6ae296
xmp.did:e06553e2-14d7-f54e-b6ae-c19b666b074c
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2017-08-09T11:08:39-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
18 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
56.231 0 Td
[(Clinical Briefs in P)18.1 (rimary Care)]TJ
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.01 Tc 7 0 0 7 40.75 373.76 Tm
(CLINICAL BRIEFS IN PRIMARY CARE)Tj
/T1_1 1 Tf
0 Tc 6 0 0 6 158.4884 373.76 Tm
(\231 )Tj
1.23 0 Td
( )Tj
-0.01 Tc -20.853 -1.167 Td
[(is published monthly by AHC Media, a Relias Learning)-10 ( )]TJ
0 -1.167 TD
[(company. Copyright \251 2017 AHC Media, a Relias Learning)-10 ( )]TJ
0.01 Tw 0 -1.167 TD
[(company.)-10 ( )]TJ
/T1_2 1 Tf
0 Tw 8 0 0 8 40.75 342.76 Tm
(Executive Editor:)Tj
/T1_1 1 Tf
( Leslie Coplin)Tj
/T1_2 1 Tf
0 -1.25 TD
(Physician Editor:)Tj
/T1_1 1 Tf
( Stephen Brunton, MD)Tj
/T1_2 1 Tf
0.01 Tw T*
(Editor:)Tj
/T1_1 1 Tf
0 Tw ( Jonathan Springston)Tj
6 0 0 6 40.75 308.76 Tm
[(This is an educational publication designed to present)-10 ( )]TJ
0 -1.167 TD
[(scientific information and opinion to health professionals,)-10 ( )]TJ
0 -1.167 TD
[(stimulate thought, and further investigation. It does not)-10 ( )]TJ
0 -1.167 TD
[(provide advice regarding medical diagnosis or treatment)-10 ( )]TJ
T*
(for any individual case. It is not intended for the layman.)Tj
0.01 Tc 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.025 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in)-25 ( )]TJ
-0.001 Tw T*
[(accordance with Accreditation Council for Continuing Medical)-25 ( )]TJ
0 Tw 0 -1.167 TD
[(Education guidelines, Dr. Brunton reports he is a retained)-25 ( )]TJ
0 -1.167 TD
[(consultant for Abbott Diabetes, Actavis, AstraZeneca, Becton)-25 ( )]TJ
T*
[(Dickinson, Boehringer Ingelheim, Cempra, Janssen, Lilly,)-25 ( )]TJ
0 -1.167 TD
[(Merck, Novo Nordisk, Sanofi, and Teva; he serves on the)-25 ( )]TJ
0 -1.167 TD
[(speakers bureau of AstraZeneca, Boehringer Ingelheim,)-25 ( )]TJ
T*
[(Janssen, Lilly, Novo Nordisk, and Teva. Dr. Kuritzky \(author\))-25 ( )]TJ
0 -1.167 TD
[(is a retained consultant for and on the speakers bureau of)-25 ( )]TJ
0 -1.167 TD
[(Allergan, Daiichi Sankyo, Lilly, and Lundbeck. Ms. Coplin, Mr.)-25 ( )]TJ
T*
[(Springston, and AHC Media Editorial Group Manager Terrey)-25 ( )]TJ
0 -1.167 TD
[(L. Hatcher report no financial relationships relevant to this)-25 ( )]TJ
0 -1.167 TD
(field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 165.734 338.51 re
S
/CS0 cs 0.1 scn
43.545 102.88 146.91 68.76 re
f
0.86 0.57 0 0.16 K
0.3 w 10 M
q 1 0 0 1 85.6163 142.0642 cm
0 0 m
80.087 0 l
S
Q
q 1 0 0 1 72.6205 135.0642 cm
0 0 m
42.017 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 48.0448 159.9401 Tm
[(SUBSCRIBER INFORMA)92 (TION)]TJ
-0.01 Tc 7 0 0 7 48.0448 149.6641 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_1 1 Tf
-0.025 Tc 6 0 0 6 48.0448 142.6641 Tm
(Email Address:)Tj
0.86 0.57 0 0.16 k
/GS1 gs
( jspringston@reliaslearning.com)Tj
0 0 0 1 k
/GS0 gs
-0.01 Tc 0.01 Tw T*
(Website: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
4.096 0 Td
(AHCMedia.com)Tj
0 0 0 1 k
/GS0 gs
0 Tw -4.096 -1.917 Td
[(Address Correspondence to: AHC Media, a Relias)-10 ( )]TJ
T*
[(Learning company, 111 Corning Road, Suite 250,)-10 ( )]TJ
T*
[(Cary, NC 27518.)-10 ( )]TJ
ET
q
81.64 94 68.84 -38.25 re
W n
q
/GS1 gs
68.8401276 0 0 38.2499963 81.6398926 55.7500113 cm
/Im0 Do
Q
Q
/CS0 CS 1 SCN
1 w
/GS1 gs
q 1 0 0 1 36 743.3608 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 36 708.2956 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 36 729.3608 Tm
[(Simplifying Pulmonary)-4.8 ( )]TJ
0 Tc 8.995 0 Td
( )Tj
-0.005 Tc -8.995 -1.148 Td
(Embolism Diagnosis)Tj
/TT1 1 Tf
0 Tc 9 0 0 9 36 690.4304 Tm
(SOURCE: van der Hulle, et al. )Tj
/TT2 1 Tf
11.962 0 Td
[(L)17.6 (ancet)]TJ
/TT1 1 Tf
( )Tj
-11.962 -1.207 Td
(2017;390:289-297.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 35.7927 652.8 Tm
(T)Tj
/T1_3 1 Tf
9.25 0 0 9.25 54.3747 663.9 Tm
(he consequences of missing pul)Tj
(-)Tj
0 -1.2 TD
(monary embolism \(PE\) are grave, )Tj
-1.986 -1.207 Td
(and numerous prediction methods have )Tj
0 -1.207 TD
(evolved to re\037ne clinicians\222 ability to )Tj
T*
[(properly identify PE. Unfortunately)91.9 (, )]TJ
T*
(increasing zeal for early identi\037cation of )Tj
T*
(PE also has led to increased proportions )Tj
T*
(of screened patients turning out to be PE-)Tj
T*
(negative. Indeed, diagnostic imaging with )Tj
0 -1.207 TD
[(CT pulmonary angiography \(CTP)55 (A\), )]TJ
0 -1.207 TD
(the test of choice for PE con\037rmation, is )Tj
0 -1.207 TD
(negative in as many as 90% of patients )Tj
0 -1.207 TD
(suspected of PE. )Tj
0 -2.414 TD
[(CTP)55 (A is not without risk, both the im)]TJ
(-)Tj
0 -1.207 TD
(mediate risk of contrast medium and )Tj
T*
(concerns about long-term radiation con)Tj
(-)Tj
T*
[(sequences. Y)86 (ou may be surprised to learn )]TJ
T*
[(that the radiation of CTP)55 (A is equivalent )]TJ
T*
(to literally 1,500 chest X-rays, so it is not )Tj
T*
[(to be undertaken lightly)92 (.)]TJ
0 -2.414 TD
(A new decision rule considered by van )Tj
0 -1.207 TD
(der Hulle et al includes three primary )Tj
T*
(items: clinical signs of deep vein )Tj
ET
/GS1 gs
q 1 0 0 1 214.008 475.56 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 214.008 424.4212 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9.25 0 0 9.25 214.008 736.8565 Tm
(thrombosis, hemoptysis, and clinical )Tj
0 -1.207 TD
(suspicion that PE is the most likely )Tj
0 -1.208 TD
(diagnosis. When coupled with D-dimer )Tj
0 -1.207 TD
(thresholds, this decision rule appears )Tj
T*
(to reduce the frequency with which )Tj
0 -1.208 TD
[(unnecessary CTP)55 (A is required. For )]TJ
0 -1.207 TD
(instance, when none of the three primary )Tj
T*
(items are present and d-Dimer is < 1,000 )Tj
0 -1.208 TD
(ng/mL, or when one to two primary )Tj
T*
(items exist but D-dimer is < 500 ng/mL, )Tj
0 -1.207 TD
[(PE is essentially excluded, and CTP)55 (A )]TJ
T*
[(is not necessary)92 (. Compared with the )]TJ
0 -1.208 TD
[(widely used W)73.9 (ells\222 rule, employment of )]TJ
0 -1.207 TD
(this decision rule resulted in a signi\037cant )Tj
0 -1.208 TD
[(diminution of the need for CTP)55 (A.)]TJ
0 -2.415 TD
(This large clinical trial \(n = 3,465\) of )Tj
0 -1.208 TD
(patients with potential PE, all of whom )Tj
0 -1.207 TD
[(underwent CTP)55 (A to con\037rm the exclu)]TJ
(-)Tj
T*
(sionary capacity of the new diagnostic )Tj
0 -1.208 TD
(scheme, suggests that we may be able to )Tj
T*
(be more ef\037cient in limiting the number )Tj
0 -1.207 TD
[(of patients who undergo CTP)55 (A. )10 ( )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
10 0 0 10 345.9211 491.1294 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 214.008 461.56 Tm
[(T)100.8 (amsulosin for Lower)-5 ( )]TJ
0 Tc 8.922 0 Td
( )Tj
-0.005 Tc -8.922 -1.148 Td
[(Urinary T)175.1 (ract Symptoms)]TJ
0 Tc 9.713 0 Td
( )Tj
-0.005 Tc -9.713 -1.148 Td
[(in W)54.5 (omen)]TJ
/TT1 1 Tf
0 Tc 9 0 0 9 214.008 406.5518 Tm
(SOURCE: Zhang HL, et al. )Tj
/TT2 1 Tf
(Int J Impot Res)Tj
/TT1 1 Tf
16.015 0 Td
( )Tj
-16.015 -1.208 Td
(2017;29:148-156.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 213.8007 368.9129 Tm
(T)Tj
/T1_3 1 Tf
9.25 0 0 9.25 232.3827 380.0129 Tm
(he umbrella term \223lower urinary )Tj
0 -1.2 TD
(tract symptoms\224 \(LUTS\) includes )Tj
-1.986 -1.207 Td
(symptoms such as dif\037culty starting )Tj
0 -1.208 TD
[(stream, dribbling, incontinence, urgency)92 (, )]TJ
0 -1.207 TD
(and incomplete emptying. In men, the )Tj
0 -1.208 TD
(most common source of LUTS is benign )Tj
0 -1.207 TD
(prostatic hyperplasia. Alpha-blockers )Tj
T*
(\(e.g., tamsulosin, alfuzosin\) are employed )Tj
0 -1.208 TD
(commonly to treat LUTS in men, based )Tj
0 -1.207 TD
(on their capacity to decrease prostatic )Tj
0 -1.208 TD
(smooth muscle tone as well as relax the )Tj
0 -1.207 TD
(musculature of the bladder neck, which )Tj
T*
(also is rich in alpha-receptors. Individual )Tj
0 -1.208 TD
(trials of alpha-blockers in women also )Tj
0 -1.207 TD
(have demonstrated improvements in )Tj
0 -1.208 TD
(LUTS.)Tj
0 -2.415 TD
(Zhang et al performed a meta-analysis )Tj
0 -1.207 TD
(of trials of the ef\037cacy of tamsulosin )Tj
T*
(in women with LUTS \(n = 764\). They )Tj
0 -1.208 TD
(found positive effects on voiding )Tj
0 -1.207 TD
(symptoms and quality of life scores. )Tj
T*
(Whereas the typical \037rst-line treatment )Tj
0 -1.208 TD
(for women with overactive bladder )Tj
T*
(usually is anticholinergics or beta-)Tj
0 -1.207 TD
(3 agonist treatment, these data also )Tj
T*
(showed a favorable effect of tamsulosin )Tj
0 -1.208 TD
(on the Overactive Bladder Questionnaire )Tj
0 -1.207 TD
(score. Clinicians who are familiar with )Tj
0 -1.208 TD
[(prescribing tamsulosin probably w)10 (i)10 (l)10 (l )]TJ
-0.01 Tc 0 -1.207 TD
[(recognize that it is generally well tolerated)-10 ( )]TJ
ET
/GS1 gs
q 1 0 0 1 392.016 640.777 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 392.016 605.4171 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9.25 0 0 9.25 392.016 736.8565 Tm
[(in men. However)111 (, long-term safety trials)-10 ( )]TJ
0 -1.239 TD
[(in women have not been conducted.)-9.9 ( )]TJ
T*
[(Decades of use of alpha-blockers to treat)-9.9 ( )]TJ
0 -1.239 TD
[(hypertension in both genders as well as)-10 ( )]TJ
0 -1.239 TD
[(the long-term data of benignity in men)-10 ( )]TJ
T*
[(reassure clinicians that tamsulosin may be)-10 ( )]TJ
T*
[(a valuable \(though off-label\) treatment for)-10 ( )]TJ
T*
(LUTS in women. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 10 0 0 10 463.5085 656.637 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 392.016 626.777 Tm
[(Observation vs. Surgery)-4.9 ( )]TJ
0 Tc 9.797 0 Td
( )Tj
-0.005 Tc -9.797 -1.169 Td
[(for Early P)17.6 (rostate Cancer)]TJ
/TT1 1 Tf
0 Tc 9 0 0 9 392.016 587.2571 Tm
[(SOURCE: W)17.7 (ilt TJ, et al. )]TJ
/TT2 1 Tf
9.386 0 Td
(N Engl J Med)Tj
/TT1 1 Tf
( )Tj
-9.386 -1.24 Td
(2017;377:132-142.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 391.8087 549.0373 Tm
(T)Tj
/T1_3 1 Tf
9.25 0 0 9.25 410.3907 560.1373 Tm
(he saga of recommendations about )Tj
0 -1.2 TD
(screening for prostate cancer contin)Tj
(-)Tj
-1.986 -1.239 Td
(ues to evolve. Whereas in 2012, the U.S. )Tj
0 -1.239 TD
[(Preventive Services T)86.1 (ask Force \(USPSTF\) )]TJ
0 -1.239 TD
(gave a \223two thumbs down\224 rating to )Tj
0 -1.239 TD
(prostate cancer screening, its 2017 posi)Tj
(-)Tj
0 -1.239 TD
(tion has softened. Although the strength )Tj
0 -1.239 TD
(of the recommendation is only level C \(at )Tj
0 -1.239 TD
(least moderate certainty that net bene\037t )Tj
T*
(is small\), the USPSTF has indicated that )Tj
T*
(for men 55-69 years of age, clinicians )Tj
T*
(should provide an individualized ap)Tj
(-)Tj
0 -1.239 TD
(proach after informing the patient about )Tj
0 -1.228 TD
(the risks and bene\037ts. For men )Tj
/C2_1 1 Tf
<0074>Tj
/T1_3 1 Tf
( 70 years )Tj
T*
(of age, the USPSTF does not recommend )Tj
0 -1.239 TD
(screening.)Tj
0 -2.478 TD
[(It\222)74 (s not clear whether you will \037nd )]TJ
0 -1.239 TD
(results of a very long-term 2017 prostate )Tj
T*
(cancer follow-up study consonant with )Tj
T*
[(the USPSTF recommendations. W)18 (ilt et )]TJ
0 -1.239 TD
(al reported on the 20-year follow-up of )Tj
0 -1.239 TD
(men with early prostate cancer treated )Tj
T*
(with surgery or observation. As was )Tj
T*
(noted on the \037rst outcomes report of )Tj
T*
(this same population in 2012, no clear )Tj
0 -1.239 TD
(advantage for surgery emerged. That is, )Tj
0 -1.239 TD
(neither all-cause mortality nor prostate )Tj
T*
[(cancer)55.1 (-related mortality was statistically )]TJ
T*
(signi\037cantly lower in men who under)Tj
16.005 0 Td
(-)Tj
-16.005 -1.239 Td
(went surgical intervention than in men )Tj
0 -1.239 TD
(who were randomized to observation. )Tj
0 -2.478 TD
(Since there were many more burden)Tj
(-)Tj
0 -1.239 TD
(some adverse effects associated with )Tj
0 -1.239 TD
(surgical intervention \(primarily erectile )Tj
0 -1.239 TD
(dysfunction and urinary incontinence\), )Tj
0 -1.239 TD
(the choice of treatment does not seem )Tj
T*
(unclear to me were I suffering early pros)Tj
(-)Tj
0 -1.239 TD
[(tate cancer)111 (, and especially low Gleason )]TJ
0 -1.239 TD
(score disease. Nonetheless, keeping in )Tj
T*
[(step with the USPSTF)129 (, clinicians are now )]TJ
T*
(encouraged to inform men 55-69 years of )Tj
T*
(age about the relative risks and bene\037ts )Tj
0 -1.239 TD
(of screening, and to individualize based )Tj
0 -1.239 TD
(on their informed decision. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
10 0 0 10 505.0034 44.9999 Tm
<0084>Tj
ET
endstream
endobj
19 0 obj
<>
endobj
25 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
26 0 obj
<>stream
How,~ FQm
-lUEhʣm
J(q mLR>TThEU5Mm'FiZPllCٙٝǾL~gs̹(iEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?QQDEOT?Q=xK<ۛљu
5+VR%26FdvqycOi[hBYe\o %e̹, V/Pq'ņB/si-lٌ[.]8⏝+L#7̛Ӌ?$s\OmfO۴kJu
,3eEϏt$/!i*L~cqMb9G&?e?+IyQ{zƔo]Rz(\W^Dy*3~i`ĸYWo٩B+(a`ָ-`Ju_ݾRƙk][|y'[lͺi㧍\,Kۓ"D#0Qhd}=`ExZlm KC}}-7tհ
NlgY]]]c?JcCn\*wYwLI]kbc$/]oUpT`Z4>?NAHOK4[RY.rOV5
ߘ~/jOKYk/
N.4x/ ks)`նGad?7U{!Dna}&C{3ꔜ86&~4r0>>𗗗;WK*f';;
0.@}{% @C_5sm8?>>6>֖btbs>hƺ6NhUgȵa&Zw8ũS-?{{i}[i 0kpW1~K|aTJR0j.W➦ ج*2Gm+%}2bjj#~DVR7d"G(-~72q,h-AMJ _ 7$x0˷G
w^Hz
=h1?2MdŔw"SSbѹlj
B2w>6v2
aaH~уƟ[78Gna
ۤ0Js;rrkReeq='|~M^PϓQ4l%:UEw hl(/\AԔ
S_V*~thA`eH)|Ξ)ߌ/WړLt0Ib7S_7`w{{{&P.طvT`̶trsZr%%I<ĥb4Q#eՂEwe^o5EW"HofL@ec0|ewX3'Ebc\'t̿Z!rX#DSoP7շ!4lzr0MLgÆ{fK]$߃73GF/e\x,n":0Ws!Tp
L}PzyꐦZ3#MM!
IC?q=?yrRsi<ݟ%xnZĿ@NP"2I|kmV\>''p5NƟjFmiO]G2 TT(v E`agVe= hh=u%HQ؈.*,jg;3xT ~NĂAW{4bG*Du_C:@aFީ3+B݄iͪp-|
2(J0gJ(S,Ma}@S:%~=k7l< ,:R#M,+_u/
֗ޟyy;b`qQ+EIX2d(I~7*g{!Ze7qC0tݪ5웨2^(?H AagP]֯ohg=Z+MU2ɹᾘ,K={8ϯzFtj(U5) !Ѡ|* (U
8'Uj34"W0υv[nATVvu#Ud9S,&~T
vv_[8р/~*K
~5anٯW+=~mOiö×[GEO!o
~Ӱws
_@?N/s!UF=GpR6ajƽ,,G" $hs?G}:.CXϖoҹ}At/8EDPdm%FZdtMPitڷfZdq0"*QQ
=r=/U7t9{{E6ww}}֢H%GN#^1Rd0km
1tSd>m(IB7VuX%OOnR~.Ϻlr_/HSO- ԺzF"O@-&DZ1'o=}E|j}WqOB_a`[z(P+ro/r68C\gu lzX'I;$W12LnjyǓsOu?e2dKIoǞ~d] RVAϺ2]$y^@Iؘ,c:_Lom$7Wlo.2M?QI^$rǟ3|[
[G,|2۟KlAvHO(~jc%AK7yi2%igZIV(חmI]9WYI$,lɽ=ɵ!U]؏P>r
OzZ'ѻ!MqȤ+GI}nhZM. b_}
$DMe^G;^gδ26dk5 yr;Ώnb
VuX7ل^Jl~WvO!V4˪2RL
/}"dƟ.ԧVt2M5UjJn&.{3/ūyxmڊEPeu>N:[7A
7554z먎_|&6G>L?ZD};~&ף,|ȲzM]xze5;#4p@6Y}2XgarDOWjG9'?t5t"gcԹBnq XF:5@Px/{25~#2ü;2h} /]ۻ4WJu{G#bhnV?^[
uVf^H)㇇at621Ift7N'U6KjLq`՞?tɾٺ;vhiL}l
Q _vqUR"p_dqTL
P8c{x٤(窎271%LeHː E;کe3 LRkG!n0glJtNkmHCQi
{$%{W{vٛT_yw